Certara
The leading drug development consultancy with solutions spanning the discovery, preclinical and clinical stages of drug development.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 Valuation: €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 14.4x EV/Revenue 195.9x EV/EBITDA | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
* | N/A | Grant | |
| Total Funding | 000k | ||
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 17 % | 17 % | 17 % | 6 % | 9 % | 9 % | 8 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 7 % | 20 % | 27 % | 20 % | 19 % | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (20 %) | (5 %) | 4 % | (16 %) | (3 %) | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 8 % | 7 % | 8 % | 10 % | 10 % | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Certara provides biosimulation software and technology-enabled services to transform the drug discovery and development process. The company's business model is centered on licensing its proprietary software and providing consulting services, serving over 2,000 biopharmaceutical companies, academic institutions, and regulatory agencies across 62 countries.
The company was formed in 2008 through the merger of Tripos International, a drug discovery informatics specialist, and Pharsight Corporation, which offered software and services for optimizing clinical trials. This merger was driven by the need for a more efficient, model-informed approach to drug development. Certara's growth has been significantly fueled by a series of strategic acquisitions, including Simcyp in 2012, Pinnacle 21 in 2021, Vyasa Analytics in 2023, and ChemAxon in 2024, continuously expanding its technological and service capabilities. In December 2020, Certara went public with an initial public offering on the Nasdaq Global Select Market under the ticker symbol "CERT", raising approximately $336.5 million in gross proceeds.
Certara's offerings cover various stages of drug development, from discovery to regulatory submission and market access. Its core products include the Simcyp® Simulator, a physiologically-based pharmacokinetic (PBPK) modeling platform, and other quantitative systems pharmacology (QSP) tools that create virtual patients to conduct computer-based trials. These simulators help predict drug efficacy, safety, and optimal dosing, and are used by clients to support regulatory submissions. The company also provides an integrated data repository, scientific informatics platforms, and AI-driven tools to streamline workflows and enhance data analysis.
William F. Feehery has been the CEO of Certara since June 2019. He holds a Ph.D. in Chemical Engineering and an MBA from MIT. Before Certara, he was the president of DuPont Industrial Biosciences. Amin Rostami-Hodjegan is the Chief Scientific Officer, a co-founder of Simcyp Limited (acquired by Certara), and a professor of Systems Pharmacology at the University of Manchester, recognized for his extensive contributions to PBPK modeling.
Keywords: biosimulation, drug development, pharmacokinetic modeling, regulatory science, model-informed drug development, clinical trial simulation, PBPK, QSP, scientific informatics, pharmaceutical services
Tech stack
Investments by Certara
Edit
